227 results about "Fibroblast growth factor" patented technology

The invention discloses an abdominal aortic aneurysm progress prediction method and system based on cross-modal knowledge distillation. The method comprises the following steps: collecting blood of a target object; the method comprises the following steps: detecting the concentration of blood protein fingerprint markers of blood of a target object, wherein the blood protein fingerprint markers comprise matrix metalloproteinase-12, calcitonin-related polypeptide-alpha, uromodulin, nerve injury induction protein-1, glycosylated hemoglobin A1c and fibroblast growth factor-9; carrying out abdominal aortic aneurysm risk calculation by calling Student-net of cross-modal knowledge distillation based on the blood protein fingerprint marker concentration; wherein the input of the Teaser-net of the cross-modal knowledge distillation comprises a CTA image feature and a pathological section feature, and a category probability vector output by the Student-net is aligned with a category probability vector output by the Teaser-net; and outputting the risk level of the abdominal aortic aneurysm and the probability of occurrence / progress / rupture of the abdominal aortic aneurysm in the preset year. And the development of the aortic aneurysm disease is accurately predicted.

The invention discloses application and a preparation method of exosome EGF-FGF-EXO containing double growth factors, the exosome EGF-FGF-EXO is uniform in particle size, high in loading efficiency and good in biological activity, the double growth factors comprise an epidermal growth factor EGF and a fibroblast growth factor FGF, and the epidermal growth factor EGF and the fibroblast growth factor FGF are added into the exosome EGF-FGF. The preparation method of the exosome EGF-FGF-EXO comprises preparation of an induced pluripotent stem cell (iPSC) exosome and loading of EGF-FGF, a recombinant epidermal growth factor (EGF) and a fibroblast growth factor (FGF) are loaded on the exosome from iPS-clone 12c, and the exosome product which has high biological activity and is used for treating nervous system diseases of neuroinflammation is prepared. The invention develops a brand new technical path for treatment of nervous system diseases, and in the fields of epilepsy, neurodegenerative diseases, brain injury and the like, the life quality of patients can be improved and important theoretical basis and technical support can be provided for precise medical treatment of nervous system diseases by precisely regulating and controlling neuroinflammation.

The invention relates to the technical field of biological products, and discloses a mesenchymal stem cell hair growth liquid and a preparation method thereof, and the mesenchymal stem cell hair growth liquid comprises the following components: hair follicle mesenchymal stem cells; a hair follicle mesenchymal stem cell exosome; growth factors: a vascular endothelial growth factor (VEGF), a fibroblast growth factor (FGFs), a keratinocyte growth factor (KGF-7) and interleukin-10 (IL-10); vitamins: vitamin E, vitamin B5, vitamin B2, vitamin B6, vitamin C and biotin; the plant extracts comprise a cacumen biotae extract, a polygonum multiflorum extract, a ginseng extract, a peppermint extract, a purslane extract and a rhodiola rosea extract; other active ingredients: tripeptide and digoxin; the auxiliary material is a hyaluronic acid-collagen peptide graft copolymer; and the balance of a phosphate buffer solution.

The invention relates to morin nanoparticles, pH responsive hydrogel and application of the morin nanoparticles and the pH responsive hydrogel. The morin-loaded nanoparticles provided by the invention can be rapidly degraded in an alkaline environment, have certain stability in an acidic environment, have the capability of releasing morin in response to pH, and can realize accurate regulation and control of morin release according to the change of environmental pH. According to the invention, hyaluronic acid is further subjected to methacrylation treatment, such that MeHA is obtained. The characteristic that MeHA is easier to degrade in an acid environment is utilized, and MeHA is used as hydrogel to load CFMNPs and can be effectively used for treating wounds caused by burns and frostbite. Furthermore, the pH responsive double-layer hydrogel based on pigment nanoparticles-basic fibroblast growth factors can realize sequential release of the effective components according to the change of the pH value of the burn or frostbite wound. The composition can effectively inhibit inflammation, resist oxidative stress, promote proliferation and migration of endothelial cells, promote neovascularization and finally accelerate wound healing.

The invention discloses a liver progenitor organoid culture medium and a culture method, and belongs to the technical field of organoid culture. The culture medium comprises a basic culture medium, Jagged-1, Dexamehysone, TGF (Transforming Growth Factor)-alpha, beta-mercaptoethanol, BMP4 (Bone Morphogenetic Protein 4), FGF2 (Fibroblast Growth Factor 2), specific addition factors Glutamax, HEPES (Hydroxyethyl PES), Nicotinamide, Penicillin and the like. The liver progenitor organoid is constructed by using the liver tissue for the first time, continuous growth and efficient proliferation of human liver progenitor cells in vitro can be promoted under the condition that gene editing is not carried out, meanwhile, the pluripotency of the liver progenitor organoid is maintained, and the consistency of specific marker expression is maintained; and a novel batch model is provided for the evaluation of hepatotoxicity at the present stage. From the long-term view, a foundation is laid for constructing a liver organ model with more advanced various differentiated cells.

The invention discloses a culture system, culture method and application of gastrointestinal tumor chemotherapy drug-resistant organoid, the culture system comprises: a basic culture medium, which is a DMEM / F12 culture medium, and is additionally added with a special growth promoting factor obtained from a natural extract; the multiple growth factors comprise an epidermal growth factor (EGF), a fibroblast growth factor (FGF), a bone morphogenetic protein (BMP) and a vascular endothelial growth factor receptor inhibitor (VEGFRi), and the concentration of each growth factor is accurately screened and optimized; the extracellular matrix is Matrigel modified by physical and chemical methods; the specific additive comprises an antioxidant N-acetylcysteine (NAC). According to the culture system, the culture method and the application of the gastrointestinal tumor chemotherapy drug-resistant organoid, the culture system which is closer to a real environment in vivo is constructed by optimizing basic culture medium components, setting various growth factors and specific additive concentrations and adopting modified Matrigel as an extracellular matrix.

The invention discloses a GLP-1 GIP analogue, an FGF21 protein, a three-function protein and an application thereof. The trifunctional protein comprises a GLP-1 / GIP analogue and an FGF21 (Fibroblast Growth Factor 21) protein. The invention also discloses application of the GLP-1 / GIP analogue, the FGF21 protein and the three-function protein in preparation of medicines for preventing and / or treating diseases related to GLP-1, GIP and / or FGF21. The GLP-1 / GIP analogue, the FGF21 protein and the three-function protein provided by the invention can synergistically regulate blood sugar and lipid levels in vivo, meet multiple requirements of patients with type 2 diabetes for reducing blood sugar, relieving liver fatty degeneration, reducing weight, improving circulating lipid metabolism disorder and the like, and are better in biological safety and tolerance and longer in in-vivo half-life period.

The invention relates to the technical field of biology, in particular to a method for producing a platelet quality control product by using iPS cells and the platelet quality control product, and the method comprises the following steps: controlling overexpression of a specific gene in the iPS cells by using a gene editing technology to obtain an iPS cell line containing the specific iPS cells; a differentiation procedure is started by adding a culture medium containing a tetracycline derivative, and meanwhile, a fibroblast growth factor 2 and a bone morphogenetic protein 4 are added to promote mesoderm differentiation; growth factors and tetracycline derivatives are added to induce overexpression of specific gene segments and promote formation of specific megakaryocytes; adding an AhR antagonist and a ROCK inhibitor into the recovered specific megakaryocyte, and culturing to obtain platelets; and screening a platelet standard substance based on platelet functions and preparing the platelet standard substance into a quality control substance.

According to various aspects of this disclosure, the present disclosure relates to methods for reducing kidney inflammation, reducing kidney fibrosis, reducing oxidative stress in the kidney, preventing or reducing the likelihood of chronic kidney disease (CKD), treating or preventing acute kidney injury (AKI) or treating a kidney disease in a subject in need thereof comprising administering, e.g., intramuscularly, to the subject a recombinant adeno-associated virus (rAAV) vector, wherein the rAAV vector comprises a vector genome comprising a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) or a functional fragment thereof and an AAV capsid (e.g., AAV1 serotype), optionally, wherein the subject does not suffer from diabetes.

The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.

The application provides a culture medium and a culture method of ovarian cancer primary cells. The culture medium comprises an MST1 / 2 kinase inhibitor, sodium pyruvate, forskolin, epidermal growth factor, gastrin, fibroblast growth factor 7, nicotinamide, SB431542, and fetal bovine serum. Compared with the existing culture method, the in-vitro culture using the culture medium of the application has higher amplification efficiency; the culture of the ovarian cancer primary cells using the culture medium can maintain the morphological structure and pathological characteristics of the primary tissue, and improve the success rate and survival rate of the ovarian cancer primary cell culture.

The present invention relates to a method for assessing whether a subject has Polycystic Ovarian Syndrome (PCOS) or is at risk of developing PCOS, to a method of selecting a patient for therapy of PCOS, to a method for monitoring PCOS progression or for monitoring response to treatment and to a computer-implemented method for assessing a subject with suspected PCOS, by determining the amount or concentration of Fibroblast Growth Factor-Binding Protein 1 (FGFBP1) in a sample of the subject.

Provided herein are polynucleotides comprising a coding sequence for expression of a fibroblast growth factor 21 (FGF21) pathway activating agent. Also provided are vectors, recombinant viral genomes, and recombinant virus compositions comprising said polynucleotides, as well as associated methods.

Compositions, methods and treatment regimens for mutant fibroblast growth factor-21 (FGF-21) peptide conjugates for the treatment of severe hypertriglyceridemia are provided.

The present application relates to the technical field of biology, and particularly relates to a mesenchymal stem cell culture medium and a preparation method and application thereof.The mesenchymal stem cell culture medium comprises a basic culture medium, fetal bovine serum, basic fibroblast growth factor, polymyxin B and deionized water.The present application can simultaneously improve the proliferation activity of mesenchymal stem cells and the secretion performance of HGF by simultaneously adding the basic fibroblast growth factor and the polymyxin B in the basic culture medium; more stem cells can be in the active proliferation and division process by limiting the content of the basic fibroblast growth factor in the mesenchymal stem cell culture medium to 5-50 ng / mL; and the secretion performance of HGF can be improved while the cell proliferation activity is maintained by limiting the content of the polymyxin B in the mesenchymal stem cell culture medium to 50-100 mu g / mL.

The invention relates to the technical field of biological medicines, in particular to a preparation method of a stem cell factor composition for promoting scalp hair follicle regeneration. The method comprises the following steps: performing high-low oxygen cycle pre-stimulation and stepped hypoxia induction on umbilical cord mesenchymal stem cells, monitoring secretion kinetics of vascular endothelial growth factors (VEGF), hepatocyte growth factors (HGF), keratinocyte growth factors (KGF) and fibroblast growth factors 2 (FGF2) in real time, and determining the optimal collection time; performing ultrafiltration on the supernate to obtain a primary concentrated solution, optimizing the molecular weight cutoff based on the bioactivity retention rate after freezing and thawing, and concentrating to obtain a stem cell factor concentrated solution; the stem cell factor composition is obtained by combining the stem cell factor with a compound nutrition preparation, verifying in-vitro hair follicle cell proliferation / migration activity, dynamically adjusting the nutrition proportion according to the relative efficiency ratio and optimizing. According to the invention, intelligent preparation of the stem cell factor composition with multi-factor synergistic secretion, controllable process, stable activity and adjustable functions is realized.

The present invention provides a primary cell culture medium for culturing primary lung cancer epithelial cells, which contains at least one of an MST1 / 2 kinase inhibitor, a ROCK kinase inhibitor, a fibroblast growth factor 7, a B27 supplement, and a N2 supplement, a hepatocyte growth factor, an insulin-like growth factor 1, an interleukin 6, and a TGFβ type I receptor inhibitor. The present invention also relates to a culturing method using the primary cell culture medium and its application in drug efficacy evaluation and screening. The culturing method uses the above-mentioned primary cell culture medium to culture primary cells on a culture vessel coated with extracellular matrix glue, so that the primary cells proliferate rapidly. The cell model obtained by the primary cell culture medium and the primary cell culturing method of the present invention can be used for drug efficacy evaluation and screening.

The invention provides a special culture medium for prostate cancer organoid and a culture method thereof, and belongs to the technical field of biological medicines. The special culture medium for the prostatic cancer organoid is composed of a basic culture medium and a culture additive, and the basic culture medium does not contain exogenously added Noggin recombinant protein and R-spondin recombinant protein. The culture additive is prepared from a basic fibroblast growth factor, a keratinocyte growth factor, a fibroblast growth factor 10, insulin, a p38MAPK signal channel inhibitor, an insulin-like growth factor 1, B27, nicotinamide, N-acetylcysteine, hydrocortisone, a ROCK kinase inhibitor, retinoic acid, interleukin 6, prostaglandin E2, a eriocin and androgen. According to the special culture medium for the prostatic cancer organoid, the culture success rate is increased while the cost is reduced.

The present invention relates to a method for assessing myocardial infarction comprising the steps of determining the amount of a first biomarker in a sample of a subject, said first biomarker being a cardiac Troponin, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a BMP10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), comparing the amounts of the biomarkers to references for said biomarkers and / or calculating a score for assessing myocardial infarction based on the amounts of the biomarkers, and assessing said subject based on the comparison and / or the calculation. The invention also relates to the use of a first biomarker being a cardiac Troponin and a second biomarker selected from the group consisting of: a BMP10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), or at least one detection agent for said first biomarker and at least one detection agent for said second biomarker for assessing myocardial infarction. Moreover, the invention further relates to a computer-implemented method for assessing myocardial infarction and a device and a kit for assessing myocardial infarction.

The invention provides a recombinant human basic fibroblast growth factor based on AI (artificial intelligence) design and a construction method of an expression vector of the recombinant human basic fibroblast growth factor, which are characterized in that on the basis of an AI artificial intelligence algorithm, a high-stability recombinant human basic fibroblast growth factor protein configuration is designed through AI aided design and mutation of protease easily-hydrolyzed sites of a human fibroblast growth factor 2, and the expression vector of the recombinant human basic fibroblast growth factor is constructed. And the high-stability human fibroblast growth factor 2 recombinant vector is constructed and prepared, so that the biological activity of the FGF2 is improved, and the durability of the drug effect is facilitated. According to the invention, the amino acid screening range can be reduced by 50-80%, the medicine research and development cycle can be shortened by 1 / 4-1 / 5, and the research and development cost can be reduced by 10-20%. And the protein drug screening efficiency is improved.

The application discloses preparation of a canine fibroblast growth factor 21 fusion protein and application thereof in treating atopic dermatitis. The application provides a caninized fibroblast growth factor 21 (FGF21) fusion protein, which is composed of a caninized fibroblast growth factor 21 (FGF21) and a fusion tag, and the fusion tag is TAT or R11 or Fc. The three kinds of FGF-21 fusion proteins obtained by the application can effectively improve the symptoms of atopic dermatitis of mice and reduce the expression level of related inflammatory factors. The three kinds of FGF-21 recombinant fusion proteins provided by the application can be used as potential drugs for treating atopic dermatitis of dogs.

The present invention provides a special culture medium for breast cancer organoids and a culture method thereof, belonging to the technical field of primary cell culture. A special culture medium for breast cancer organoids is composed of a basal medium and culture additives. The basal medium is DMEM / F12 medium, and the culture additives are composed of epidermal growth factor, basic fibroblast growth factor, keratinocyte growth factor, fibroblast growth factor 10, insulin, transferrin, sodium selenite, A83-01, SB202190, insulin-like growth factor 1, B27, nicotinamide and N-acetylcysteine. The culture medium of the present invention improves the stability of the tumor cell genome during the culture while reducing the culture cost.

To provide a novel medium for propagating liver organoids that achieves cost reduction compared to conventional media.SOLUTION: The present invention provides a medium for propagating human pluripotent stem cell-derived liver organoids, the medium comprising a culture supernatant of modified L cells, which are L cells modified so as to express R-spondin-1, hepatocyte growth factor (HGF), fibroblast growth factor (FGF) 7, and fibroblast growth factor 10.SELECTED DRAWING: Figure 5

To provide a method for producing a sheet-like cell culture showing a three-layer structure including a cell layer of superficial cells, a cell layer of intermediate cells, and a cell layer of basal cells, in this order. Provided is a method for producing a sheet-like cell culture that includes culturing a progenitor cell population in a second compartment separated from a first compartment via a porous member to form a sheet-like cell culture in the second compartment. The sheet-like cell culture includes a cell layer of superficial cells derived from the progenitor cell population, a cell layer of intermediate cells derived from the progenitor cell population, and a cell layer of basal cells derived from the progenitor cell population, in this order. The first compartment holds an induction medium containing retinoic acid, bone morphogenetic protein (BMP), and fibroblast growth factor (FGF).

The utility model discloses a nozzle stable moving mechanism for FGF (Fibroblast Growth Factor) molten granular material printing, which belongs to the field of FGF molten granular materials and comprises a printer main body consisting of a printing platform and a bracket, and the printing platform is arranged on the bracket; according to the nozzle stable moving mechanism for FGF molten particle material printing, the motor, the eccentric wheel, the sliding rod and the spring are arranged, the fixed plate is supported through the effect of the supporting plate, the motor is combined to drive the rotating shaft to rotate, the eccentric wheel is matched, the movable plate is jacked upwards through rotation of the eccentric wheel, and the elastic effect of the sliding rod and the spring is combined; and when the eccentric wheel moves away from the movable plate, the movable plate can automatically reset downwards under the counter-acting force of the spring, so that a printed object on the printing platform is jacked up under the action of repeated up-and-down movement of the movable plate, the object is separated from the printing platform, time and labor are saved, and the printing efficiency is improved. And stable moving work of the nozzle is ensured.

The application provides a kind of nasal mucosa in vitro culture method and culture fluid, the composition of the culture fluid includes Wnt / β-catenin signal pathway activator 0.1-20 μg / ml, fibroblast growth factor 10-150 ng / ml, TGF-β inhibitor 0.02-3 μg / ml, ROCK inhibitor 0.1-100 μmol / L, P38 MAPK inhibitor 0.1-1 μmol / L, serum-free additive 1X, N-acetyl cysteine 1-10 mmol / L, nicotinamide 1-20 mmol / L, GlutaMax additive 1X, antibiotic, DMEM / F12 culture medium 1X.The application can carry out in vitro culture to nasal mucosa, can keep at least 2 weeks of activity, and have complete epithelial barrier and immune system, can realize ex vivo nasal mucosa virus infection experiment.

To provide a gene construct for use in the treatment of a metabolic disorder in a mammal, particularly a human.SOLUTION: A gene construct provided comprising a nucleotide sequence encoding fibroblast growth factor 21 (FGF21) for use in the treatment and / or prevention of a metabolic disorder, wherein the therapy involves expression of the gene construct in the central nervous system (CNS), preferably in the brain, more preferably in the hypothalamus and / or cortex and / or hippocampus and / or cerebellum and / or olfactory bulb, and most preferably in the hypothalamus.SELECTED DRAWING: None

Provided herein are methods of treating a mitral valve disease in a subject. The method comprises administering to the subject a gene therapy comprising a first nucleic acid encoding soluble transforming growth factor beta receptor 2 (sTGF beta R2) and a second nucleic acid encoding fibroblast growth factor 21 (FGF 21). Also provided are methods of treating a mitral valve disease in a subject comprising administering a gene therapy to the subject in combination with an additional therapeutic agent (e.g., pimobendan).

Provided is a method for inducing differentiation into nerve cells, the method comprising: a) culturing mesenchymal stem cells for 1-10 days in a stem cell culture medium configured by including a basal medium at 60.0–90.0 vol% and physiological saline at 10.0–40.0 vol%, the culture medium being further supplemented with 1.0–100.0 ng / mL of EGF, 0.2–20.0 ng / mL of FGF-2, 0.2–20.0 ng / mL of PDGF, and 0.5–8.0 mM of magnesium ascorbyl phosphate; b) thereafter, precipitating protein components from the culture solution obtained in step a) using an organic solvent; and c) isolating the precipitate portion and dissolving the same in a physiological saline or a basal medium to obtain a medium comprising a cell-produced protein (CPPs) composition, and seeding, using the medium, the mesenchymal stem cells at a density of 3×103 to 2×104 cells / mL and culturing for 1-3 days, thereby inducing differentiation of the mesenchymal stem cells into nerve cells.

This specification describes modified fibroblast growth factor (FGF) polypeptides, pharmaceutical compositions and drugs comprising such modified FGF polypeptides, and methods of using such modified FGF polypeptides to treat or prevent diseases for which FGF administration is beneficial.